You just read:

Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need

News provided by

Daiichi Sankyo Company, Limited

May 08, 2019, 02:00 ET